Summit Therapeutics (SMMT) Change in Acquisitions & Divestments (2023 - 2025)
Summit Therapeutics' Change in Acquisitions & Divestments history spans 3 years, with the latest figure at $150.8 million for Q2 2025.
- For Q2 2025, Change in Acquisitions & Divestments rose 115.45% year-over-year to $150.8 million; the TTM value through Dec 2025 reached $311.3 million, down 36.44%, while the annual FY2025 figure was $311.3 million, 36.44% down from the prior year.
- Change in Acquisitions & Divestments reached $150.8 million in Q2 2025 per SMMT's latest filing, down from $160.5 million in the prior quarter.
- In the past five years, Change in Acquisitions & Divestments ranged from a high of $233.0 million in Q4 2024 to a low of $38.2 million in Q2 2023.
- Average Change in Acquisitions & Divestments over 3 years is $112.1 million, with a median of $109.4 million recorded in 2023.
- The largest YoY upside for Change in Acquisitions & Divestments was 284.66% in 2024 against a maximum downside of 32.37% in 2024.
- A 3-year view of Change in Acquisitions & Divestments shows it stood at $60.6 million in 2023, then skyrocketed by 284.66% to $233.0 million in 2024, then plummeted by 35.27% to $150.8 million in 2025.
- Per Business Quant, the three most recent readings for SMMT's Change in Acquisitions & Divestments are $150.8 million (Q2 2025), $160.5 million (Q1 2025), and $233.0 million (Q4 2024).